Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

EndoChoice study supports Fuse Full Spectrum Endoscopy System

EndoChoice announced the release of study data supporting the efficacy of the Fuse Full Spectrum Endoscopy System. These studies were presented simultaneously by leading gastroenterologists at the American College of Gastroenterology Annual Scientific Session in Philadelphia, PA, and the United European Gastroenterology Week in Vienna, Austria.

30 Oct 2014

FIT screening may be as effective as colonoscopy in detecting familial colorectal cancer

Fecal immunochemical tests (FIT) may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

30 Oct 2014

RNF43 mutation may serve as biomarker that identifies colorectal, endometrial cancer patients

Scientists say they have identified in about 20 percent of colorectal and endometrial cancers a genetic mutation that had been overlooked in recent large, comprehensive gene searches. With this discovery, the altered gene, called RNF43, now ranks as one of the most common mutations in the two cancer types.

27 Oct 2014

Financial burden higher in patients treated for colorectal cancer

Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

27 Oct 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

Hormone loss may cause colon cancer, say Thomas Jefferson University researchers

Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.

12 Oct 2014

NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

The National Comprehensive Cancer Network has published the 20th annual editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon and Rectal Cancers, two of the eight original NCCN Guidelines published in November 1996.

10 Oct 2014

VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, today announced that further data analysis from its colorectal cancer study was presented today at the 9th International Conference of Anticancer Research, being held October 6-10, 2014 in Sithonia, Greece.

9 Oct 2014

University of Luxembourg researchers identify potential new ways to test colorectal cancer

Researchers at the University of Luxembourg have identified potential new ways to test for the first signs of one of the most deadly types of cancer: colorectal cancer. They have found new "biomarkers": molecules whose increased presence or absence in tissue suggests the development of tumorous cells. These indicators could help detect colorectal cancer at an early stage, predict its severity or even offer new treatments.

9 Oct 2014

Researchers generate fruit fly model, unveil key genetic factors behind human colon cancer

Researchers at the Institute for Research in Biomedicine (IRB Barcelona) have managed to generate a fruit fly (Drosophila melanogaster) model that reproduces human colon cancer. With two publications appearing in PLoS One and EMBO Reports, the IRB team also unveil the function of a key gene in the development of the disease.

9 Oct 2014

Cancer Network presents exclusive coverage of ESMO 2014 Congress

UBM Medica US announces that Cancer Network, a leading online community for oncologists and others who treat cancer and the online home of the journal ONCOLOGY, presents exclusive coverage of the European Society for Medical Oncology (ESMO) 2014 Congress, held September 26–30 in Madrid, Spain.

8 Oct 2014

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile.

8 Oct 2014

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015.

7 Oct 2014

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

DanDrit Biotech A/S ("DanDrit Denmark"), the subsidiary of DanDrit Biotech USA, Inc. ("DanDrit"), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino" - IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa.

30 Sep 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Retrospective study finds overuse of colonoscopies for colorectal cancer screening, surveillance

A retrospective study led by researchers at Brigham and Women's Hospital (BWH), has found an overuse of colonoscopies for colorectal cancer screening and surveillance.

30 Sep 2014

Survey: Many patients not always well informed about treatment options

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid.

29 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

EndoChoice study supports Fuse Full Spectrum Endoscopy System

FIT screening may be as effective as colonoscopy in detecting familial colorectal cancer

RNF43 mutation may serve as biomarker that identifies colorectal, endometrial cancer patients

Financial burden higher in patients treated for colorectal cancer

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Hormone loss may cause colon cancer, say Thomas Jefferson University researchers

NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

University of Luxembourg researchers identify potential new ways to test colorectal cancer

Researchers generate fruit fly model, unveil key genetic factors behind human colon cancer

Cancer Network presents exclusive coverage of ESMO 2014 Congress

GenomOncology, med fusion partner to optimize treatment strategies for tumor

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Retrospective study finds overuse of colonoscopies for colorectal cancer screening, surveillance

Survey: Many patients not always well informed about treatment options

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

NCCN ORP awards four research grants to advance development of nintedanib

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in